Failure of hirudin or neutrophil elastase inhibitor to affect antithrombin III–induced chemotaxis or deactivation
| Treatment . | Neutrophil migration versus . | ||
|---|---|---|---|
| Medium . | IL-8 [1 nM] . | AT III [1 U] . | |
| Medium | 1.000 ± 0.00 | 2.147 ± 0.18 | — |
| AT III [1 U] | 1.045 ± 0.07 | 1.476 ± 0.06 | — |
| + EI [0.1 μM/L] | 1.105 ± 0.03 | 1.537 ± 0.12 ns | — |
| + EI [1 μM/L] | 0.978 ± 0.05 | 1.301 ± 0.14 ns | — |
| + EI [10 μM/L] | 1.006 ± 0.03 | 1.509 ± 0.15 ns | — |
| + EI [100 μM/L] | 1.104 ± 0.08 | 1.313 ± 0.13 ns | — |
| IL-8 [1 nM] | 1.201 ± 0.09 | 1.132 ± 0.11 | — |
| Medium | 1.000 ± 0.00 | — | 1.584 ± 0.07 |
| Hirudin [0.01 mg/mL] | 1.159 ± 0.03 | — | 1.484 ± 0.11 ns |
| Hirudin [0.1 mg/mL] | 1.150 ± 0.09 | — | 1.586 ± 0.10 ns |
| Hirudin [1 mg/mL] | 1.150 ± 0.08 | — | 1.428 ± 0.09 ns |
| Hirudin [5 mg/mL] | 1.037 ± 0.04 | — | 1.481 ± 0.08 ns |
| Treatment . | Neutrophil migration versus . | ||
|---|---|---|---|
| Medium . | IL-8 [1 nM] . | AT III [1 U] . | |
| Medium | 1.000 ± 0.00 | 2.147 ± 0.18 | — |
| AT III [1 U] | 1.045 ± 0.07 | 1.476 ± 0.06 | — |
| + EI [0.1 μM/L] | 1.105 ± 0.03 | 1.537 ± 0.12 ns | — |
| + EI [1 μM/L] | 0.978 ± 0.05 | 1.301 ± 0.14 ns | — |
| + EI [10 μM/L] | 1.006 ± 0.03 | 1.509 ± 0.15 ns | — |
| + EI [100 μM/L] | 1.104 ± 0.08 | 1.313 ± 0.13 ns | — |
| IL-8 [1 nM] | 1.201 ± 0.09 | 1.132 ± 0.11 | — |
| Medium | 1.000 ± 0.00 | — | 1.584 ± 0.07 |
| Hirudin [0.01 mg/mL] | 1.159 ± 0.03 | — | 1.484 ± 0.11 ns |
| Hirudin [0.1 mg/mL] | 1.150 ± 0.09 | — | 1.586 ± 0.10 ns |
| Hirudin [1 mg/mL] | 1.150 ± 0.08 | — | 1.428 ± 0.09 ns |
| Hirudin [5 mg/mL] | 1.037 ± 0.04 | — | 1.481 ± 0.08 ns |
IL-8 indicates interleukin-8; AT III, antithrombin III; ns, not significant.